Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




More Training Needed to "Achieve a Good Death for All"
Link ID 28902
Title More Training Needed to "Achieve a Good Death for All"
Url http://www.medscape.com/viewarticle/729051?src=rss
Description In a series of articles specially commissioned by BMJ, several commentators call for more training for those caring for the dying. Medscape Medical News
Category Articles > Hematology-Oncology
Keywords
Date Sep 22, 2010
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Hematology-Oncology
1. FDA Approves Pazopanib for Advanced Soft Tissue SarcomaFDA Approves Pazopanib for Advanced Soft Tiss
  The tyrosine kinase inhibitor pazopanib has received approval for the treatment of advanced soft tissue sarcoma in previously treated patients. FDA Approvals
Category:   Articles > Hematology-Oncology


2. Translating p53 into the Clinic
  The TP53 gene is mutated in half of reported cancer cases and the p53 pathway is often partially inactivated in the remaining half. This Review discusses the future of p53-based therapy. Nature Reviews Clinical Oncology
Category:   Articles > Hematology-Oncology


3. FDA Approves Brentuximab for Refractory LymphomasFDA Approves Brentuximab for Refractory Lymphomas
  Study data reveal a high response rate for patients with refractory Hodgkins and systemic anaplastic large cell lymphoma. br / iMedscape Medical News/i
Category:   Articles > Hematology-Oncology


4. Hormone Therapy in Prostate Cancer: Study Offers Clear Guidance
  Those with prostate cancer and high metastatic risk benefit from 3 years of hormone therapy, plus radiation. So why are doctors recommending a shorter duration? Dr. Gerald Chodak explores the issues. Medscape Urology
Category:   Articles > Hematology-Oncology


5. Improved Survival in CRC; Regorafenib Study HaltedImproved Survival in CRC; Regorafenib Study Halted
  A pivotal phase 3 trial was stopped when an interim analysis revealed that patients on the investigational drug had significantly longer overall survival. Medscape Medical News
Category:   Articles > Hematology-Oncology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS